secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001493152-24-014848
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus appoints Pershing as CEO and Rodrigues as President effective April 16
--------------------------------------------------------------------------------

- Ed Pershing appointed CEO effective April 16; will continue as Board Chairman; salary $240,000/year.
- Dominic Rodrigues appointed President effective April 16; will continue as Vice Chairman; salary $240,000/year.
- Both executives have employment agreements with change-in-control severance provisions.
- Rodrigues' prior independent contractor agreement (March 2024) terminated; he had served as chief operating consultant.
- Press release outlines 2024 focus: pancreatic cancer clinical program, capital raising at fair valuation, and enhanced investor outreach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer